I wasn't aware of the Triozzi pilot study. Not sure how I missed it. So, I read the abstract at pub med, then I read every post here on it, as well as every response, and responses response, etc. And wow... The related patent is especially encouraging. The pilot study alone is encouraging: 10 patients, 3 with breast carcinoma and 7 with malignant melanoma. 4 out of the 7 melanoma and 2 out of the 3 b.c. patients showed a response. 1 melanoma patient had a complete localized response and further showed systemic response. Most had a 50% or greater reduction in tumor mass prior to removal.
And then the patent. I was aware of what separated DCVax Direct from other localized immunotherapy treatments, namely the DC maturation point at which they can best take up the tumor's antigens and display them to the "attackers" of the immune system, and are the most mobile in getting to the lymph nodes to initiate this action (first came across that via NWBO's own investor presentation). These attackers then do just that, destroying the tumor(s). The systemic response is the most important part of this equation though, as otherwise it would be impossible to keep up with such aggressive metastasis. And that's what was seen in Triozzi. And THAT'S what I think their delay in reporting results all this time is because of--the mass of concrete SYSTEMIC data that has been mounting. The first patient was treated in June of last year. That's a long time ago considering how fast (4-6 weeks) significant responses were seen in the Triozzi pilot study.
I'm incredibly encouraged, and even more miffed I'm unable to add more shares at the moment (though that will soon change). HOWEVER, I still think viewing Direct as the successor to chemo is... for sure premature. It's a nice thought, but...
